Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000-2018.

EClinicalMedicine · 2023 · PMC10344829 · PMID 37457112

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Additionally, we observed a borderline significant decline in tMDS/AML risks over the study period, with lower SIRs particularly in the most recent calendar period, following mantle cell lymphoma (P trend = 0.054), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (P trend = 0.067), and plasma cell neoplasms (P trend = 0.051).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.